Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AHDP | ISIN: CH0308403085 | Ticker-Symbol: GEM
Frankfurt
06.06.25 | 08:04
0,060 Euro
+3,45 % +0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENEURO SA Chart 1 Jahr
5-Tage-Chart
GENEURO SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0700,07206.06.

Aktuelle News zur GENEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.GeNeuro SA Announces Definitive Debt-Restructuring Moratorium295 Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
12.05.GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results344Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of...
► Artikel lesen
28.01.GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium523Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
GENEURO Aktie jetzt für 0€ handeln
06.12.24New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro's GNK-301 Presented at the 35th International Symposium on ALS/MND841Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
30.09.24GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings574Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
19.09.24GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model551Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
28.08.24XFRA GEM: WIEDERAUFNAHME/RESUMPTION405FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
05.08.24XFRA GEM: AUSSETZUNG/SUSPENSION403DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGENEURO SA SF-,05...
► Artikel lesen
15.07.24GeNeuro Announces That It Submits a Request for a Debt Moratorium to the Geneva Court of First Instance417Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS)...
► Artikel lesen
10.07.24GeNeuro SA: End of the Liquidity Contract With GILBERT DUPONT397Regulatory News: GeNeuro SA (Paris:GNRO) and GILBERT DUPONT have terminated the liquidity contract entered into on March 6, 2021. This termination took effect on June 30, 2024, after market...
► Artikel lesen
03.07.24Geneuro SA: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont437Market: Euronext Paris ISIN code Mnemo: CH0308403085 GNRO Web site: www.geneuro.com Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont...
► Artikel lesen
28.06.24GeNeuro Announces Results of the GNC-501 Study in Post-Covid-19 Syndrome462Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO): The GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric syndromes, testing temelimab...
► Artikel lesen
14.06.24GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting81781.54% of the Company's share capital was represented at the AGM and resolutions were all unanimously approved Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1